Загрузка...
Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Lung Cancers
EGFR mutations identify patients who are more likely to respond to treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) than cytotoxic chemotherapy. The distinct success of the first generation EGFR TKIs erlotinib and gefitinib has been accompanied by the observati...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3673302/ https://ncbi.nlm.nih.gov/pubmed/23411383 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|